Latest Breaking News On - Effector therapeutics inc - Page 1 : comparemela.com

eFFECTOR Therapeutics (NASDAQ:EFTR) Trading Up 2 4%

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Free Report)’s stock price traded up 2.4% during mid-day trading on Thursday . The company traded as high as $1.73 and last traded at $1.70. 40,296 shares were traded during trading, a decline of 85% from the average session volume of 275,058 shares. The stock had previously closed at […]

Securities exchange commissionEffector therapeutics incGet free reportPoint capitalFree report

EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 eFFECTOR Therapeutics, Inc. , a leader in the development of selective translation regulator inhibitors for the treatment of cancer,.

United statesPanagiotis konstantinopoulosMichael fitzhughChristopherm calabreseKevin gardnerDoug warnerLifesci communicationsProfessor of medicine at harvard medical schoolDana farber cancer instituteExchange commissionEffector therapeutics incTranslational researchDivision of gynecologic oncologyGynecologic oncologyAssociate professorHarvard medical

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesDoug warnerMichael fitzhughPanagiotis konstantinopoulosKevin gardnerChristopherm calabreseEffector therapeutics incLifesci communicationsExchange commissionDivision of gynecologic oncologyTranslational researchDana farber cancer instituteProfessor of medicine at harvard medical schoolInvestigator sponsored phaseTrial evaluating zotatifinCombination treatment

EFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

EFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesJennifer caswell jinChristopherm calabreseChristian curtisKevin gardnerMike tattorySteve worlandExchange commissionNorthwestern universityRoberth lurie comprehensive cancer centerLifesci communicationsDevelopment rd expensesEffector therapeutics incAntonio breast cancer symposiumStanford medicineAssistant professor

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesKevin gardnerChristian curtisChristopherm calabreseJennifer caswell jinSteve worlandMike tattoryNorthwestern universityEffector therapeutics incDevelopment rd expensesRoberth lurie comprehensive cancer centerExchange commissionLifesci communicationsReports first quarterProvides corporateAntonio breast cancer symposium